Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

XML

Clinical/translational cancer immunotherapy

Original research

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

Online download statistics by month:

Online download statistics by month: August 2021 to March 2024

	Abstract	Full	Pdf
Aug 2021	268	268	107
Sep 2021	392	393	169
Oct 2021	225	225	72
Nov 2021	175	174	79
Dec 2021	229	231	107
Jan 2022	124	126	49
Feb 2022	82	88	42
Mar 2022	146	151	79
Apr 2022	134	145	40
May 2022	118	121	66
Jun 2022	140	144	60
Jul 2022	101	104	41
Aug 2022	127	136	68
Sep 2022	148	149	50
Oct 2022	164	169	60
Nov 2022	104	106	52
Dec 2022	147	149	40
Jan 2023	87	87	43
Feb 2023	165	165	49
Mar 2023	82	87	27
Apr 2023	82	82	34
May 2023	80	81	28
Jun 2023	60	61	25
Jul 2023	69	72	45
Aug 2023	74	76	21
Sep 2023	75	75	19
Oct 2023	111	111	33
Nov 2023	73	74	22
Dec 2023	101	104	33
Jan 2024	64	66	31
Feb 2024	49	49	17
Mar 2024	106	110	57
Total	4102	4179	1665